MTNB Stock Forecast: Matinas BioPharma Holdings, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$0.80

Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 39 of 100 as at 21 Nov 2026 — in the lower half.

Market cap
$902,069.00
Ticker Nerd rank
39/ 100
Median analyst target
—
Analysts covering
—
Revenue$0.0
Operating income−$1.6M
Net income−$1.3M
Free cash flow−$1.8M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Matinas BioPharma Holdings, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
39/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
97
Growth
65
Issuance
60
Volatility
36
Momentum
22
Revisions
20
Quality
18
Value
12

Accruals (97): Reported profit is backed by cash, and the company is not expanding recklessly.

Value (12): The shares cost a lot relative to the profits and assets behind them.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

MTNB stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on MTNB, reported as data — targets and ratings, the market's view beside the model's.

We don’t hold enough price history for this company yet.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
31 Oct 2024Maxim GroupDowngradeHold—
11 Oct 2023BTIGReinstatesBuy$3.00
31 Jan 2023HC Wainwright & Co.ReiteratesBuy—
13 Aug 2020Aegis CapitalMaintainsBuy—
27 Jan 2020Piper SandlerInitiatesOverweight—
24 Jan 2020SunTrust Robinson HumphreyInitiatesBuy—
26 June 2019H.C. WainwrightInitiatesBuy—
26 June 2019HC Wainwright & Co.InitiatesBuy—
17 May 2019BTIGInitiatesBuy—
17 May 2019BTIG ResearchInitiatesBuy—
11 Feb 2019Roth CapitalInitiatesBuy—
13 Nov 2018Maxim GroupMaintainsBuy—
13 Aug 2018Maxim GroupMaintainsBuy—
10 July 2018Maxim GroupMaintainsBuy—
1 Nov 2016Aegis CapitalInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

MTNB appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Estimates

MTNB analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
—
Price / book
0.3×

Cheaper than 91% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
—
Net margin
—
Returns & dividend
Return on equity
−147.5%

Higher than 10% of US stocks

Return on assets
−60.7%

Higher than 6% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Matinas BioPharma Holdings, Inc. has a market value of $902K.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$6.7M.

  • Free cash flow in the twelve months to 30 June 2026: −$6.4M.

  • Shares outstanding: 6.4M.

  • Matinas BioPharma Holdings, Inc. employs 2 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 20 Nov 2026

Data provided by Twelve Data

Peers

MTNB and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
MTNBMatinas BioPharma Holdings, Inc.$902,069.0039
KPTIKaryopharm Therapeutics, Inc.$901,700.00—
BBLGBone Biologics Corp.$910,000.0037
SLXNSilexion Therapeutics Corp.$830,400.0028
LNAILunai Bioworks, Inc.$829,700.00—
GOVXGeoVax Labs, Inc.$985,500.0031
VBIOValion Bio, Inc.$1.0M2

Take a look at MTNB’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Matinas BioPharma Holdings, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about MTNB

How does Ticker Nerd's model rank MTNB?

As at 21 Nov 2026, Matinas BioPharma Holdings, Inc. ranks 39 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Accruals (97 of 100).

What is the MTNB stock forecast for 2030?

No analyst covering Matinas BioPharma Holdings, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for MTNB are extrapolating price history, which says nothing about the business.

What does Matinas BioPharma Holdings, Inc. do?

Matinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company focused on developing pharmaceutical products using its lipid nanocrystal (LNC) delivery technology. The company’s platform is designed to support the delivery of a range of therapeutic modalities, including small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides.

Company

About Matinas BioPharma Holdings, Inc.

Matinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company focused on developing pharmaceutical products using its lipid nanocrystal (LNC) delivery technology. The company’s platform is designed to support the delivery of a range of therapeutic modalities, including small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its current work has centered on anti-infective applications, including MAT2203, an oral formulation of amphotericin B, alongside additional discovery programs in oncology and inflammation. Matinas BioPharma Holdings, Inc. operates from Bedminster, New Jersey and remains positioned as a developer of novel drug-delivery solutions within the healthcare and biotechnology market.

CEO Mr. Jerome D. Jabbour J.D. · 2 employees · United States · https://www.matinasbiopharma.com